drug_type
RELEVANT_DRUG
intervention_type
Biologic
drug_description
An engineered trispecific NK cell engager (TriKE) composed of anti-CD16, an IL-15 moiety, and anti-CD33 domains; designed to bridge NK cells via CD16 to induce cytotoxicity, deliver IL-15 to expand/sustain NK cells via JAK/STAT signaling, and target CD33+ leukemic blasts and myeloid-derived suppressor cells; administered as a single-agent continuous infusion in 28-day cycles.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Fusion Proteins, Immunologic
drug_category
TRISPECIFIC NK ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Engineered TriKE that binds CD16 on NK cells and CD33 on target myeloid cells to form an immune synapse and trigger NK-mediated cytotoxicity; includes an IL-15 moiety to activate and expand NK cells via JAK/STAT signaling, enhancing sustained killing of CD33+ leukemic blasts and MDSCs.
drug_name
GTB-360
nct_id_drug_ref
NCT06594445